犬用疫苗市场－全球产业规模、份额、趋势、机会与预测：疫苗类型、疾病类型、免疫持续时间、给药途径、地区和竞争格局（2021-2031年）

全球犬用疫苗市场预计将从 2025 年的 19.7 亿美元成长到 2031 年的 28.8 亿美元，复合年增长率为 6.53%。

这些生物製药对于刺激犬隻免疫系统抵抗某些病原体（例如狂犬病和犬瘟热）至关重要。推动市场成长的主要因素是人们对通用感染疾病的认识不断提高，这些疾病需要严格的预防保健；此外，宠物人性化趋势也增加了兽医服务的支出。根据美国兽医协会（AVMA）预测，到2024年，美国犬隻数量将达到约8,970万隻，凸显了庞大的基本客群对市场需求的巨大推动作用。

然而，市场扩张面临许多重大障碍：产品研发和核准的法规结构十分复杂。製造商必须遵守严格的安全通讯协定并大规模的临床试验，这需要大量的投资和时间。这种严格的监管环境往往会延缓创新疫苗的上市，并限制不同地区（合规标准各异）的市场进入，最终减缓整个产业的成长速度。

市场驱动因素

宠物人性化的趋势和宠物饲养率的不断上升，从根本上改变了人们对犬类疫苗的需求。随着饲主越来越将犬隻视为家庭成员而非工作动物，他们更愿意投资于全面的医疗保健，并提倡严格遵守兽医通讯协定，以最大限度地延长宠物的寿命。例如，英国宠物食品协会发布的《2024年宠物数量报告》预测，到2024年3月，英国的犬隻数量将达到1350万隻，这凸显了犬隻数量的高密度，需要持续接种疫苗以维持群体免疫。

同时，通用和感染疾病的蔓延是市场成长的主要驱动力，促使政府主导严格的管制措施。当局正在强制推行疫苗接种，以防止狂犬病等高致死性病原体的爆发，这些病原体也对人类构成威胁。越南政府入口网站于2024年3月发布的一项指令凸显了这种紧迫性，该指令要求在今年稍早发生22例狂犬病相关死亡事件后即时进行疫苗接种。为了支撑这一产业规模，硕腾公司在2024年2月的财务报告中公布了85亿美元的总收入，这反映出其在动物用药品研发方面获得了雄厚的资金支持。

市场挑战

全球犬用疫苗市场面临的主要障碍之一是兽用生技药品监管框架的复杂性。这种分散的国际格局要求严格的安全通讯协定、有效性测试和强制性临床试验，迫使製造商在特定地区的合规性方面投入巨资，并导致研发资源分散。因此，这些严格的标准提高了进入门槛，阻碍了小型生技公司的进入，并将市场力量集中在少数几个主要企业手中。

此外，漫长的核准週期显着延缓了新型免疫解决方案的商业化进程，并阻碍了业界应对新兴感染疾病的能力。根据2024年动物健康研究所的数据，新型兽用生技药品的审查和核准流程需要五到七年。如此漫长的流程限制了製造商产品推出的速度，而维持研发阶段的高昂成本则降低了投资报酬率，并限制了新疫苗上市的频率。

市场趋势

犬类肿瘤治疗中免疫疗法的兴起标誌着治疗方式从单纯的预防性医疗转向治疗性生物干预，利用自体肿瘤抗原或重组蛋白标靶治疗骨肉骨癌等恶性肿瘤。这种方法为传统化疗提供了一种精准的替代方案，可降低全身毒性，旨在延长进行性肿瘤患者的存活期。根据 Vet Candy 于 2025 年 8 月报道，一项新型 EGFR/HER2 标靶疫苗的临床试验显示，12 个月存活率显着提高，从约 35% 提高到 60%。

同时，重组和DNA疫苗技术的应用正在重塑疫苗生产流程，以基因工程载体取代传统的灭活病原体。这项技术能够生产高纯度、非感染性抗原，从而提高安全性，并实现对感染动物和接种动物的区分（DIVA），这对于疾病根除至关重要。主要企业正在扩大这些平台的规模，默克动物保健公司在2025年2月宣布的59亿美元年收入便是明证，这凸显了商业性对先进动物保健技术的强劲需求。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球犬用疫苗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依疫苗类型（减毒活病毒疫苗、不活化疫苗、其他）
  • 依疾病类型分类（犬瘟热、犬传染性呼吸道疾病症候群 (CIRDC)、犬小病毒感染疾病/细小病毒病、犬钩端螺旋体病、犬莱姆病、犬传染性肝炎、犬狂犬病等）
  • 免疫持续时间（1年、3年或其他）
  • 给药途径（注射、鼻腔、口服）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美犬用疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲犬用疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区犬用疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲犬用疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美犬用疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球犬用疫苗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Zoetis Inc.
• Bioveta as
• Hester Biosciences Limited
• Boehringer Ingelheim International GmbH
• Brilliant Bio Pharma Private Limited
• Heska Corporation
• Merck & Co., Inc.
• Virbac SA
• Zendal Group
• Elanco Animal Health Incorporated

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Dog Vaccines Market is projected to expand from USD 1.97 Billion in 2025 to USD 2.88 Billion by 2031, registering a CAGR of 6.53%. These biological preparations are essential for stimulating canine immune systems against specific pathogens like rabies and distemper. Growth is primarily fuelled by heightened awareness of zoonotic diseases, necessitating rigorous preventive care, alongside the trend of pet humanization which increases spending on veterinary services. According to the American Veterinary Medical Association, the United States dog population stood at approximately 89.7 million in 2024, highlighting the vast customer base driving demand.

However, market expansion faces a significant hurdle in the form of complex regulatory frameworks governing product development and approval. Manufacturers must adhere to stringent safety protocols and extensive clinical trials, requiring substantial investment and time. This rigid landscape often delays the release of innovative vaccines and restricts market access across regions with varying compliance standards, effectively slowing the industry's overall growth trajectory.

Market Driver

The trend of pet humanization and rising ownership rates are fundamentally altering the demand for canine immunizations, as owners increasingly view dogs as family members rather than working animals. This shift promotes a willingness to invest in comprehensive preventive healthcare, ensuring rigorous adherence to veterinary protocols to maximize pet longevity. For instance, UK Pet Food's 'Pet Population 2024' report noted that the United Kingdom's dog population reached 13.5 million in March 2024, emphasizing the dense population requiring consistent vaccination for herd immunity.

Simultaneously, the prevalence of zoonotic and infectious diseases serves as a major catalyst for market growth, prompting strict government-led control measures. Authorities are enforcing vaccination mandates to prevent outbreaks of high-mortality pathogens like rabies, which poses risks to humans. The urgency is evident in the Vietnam Government Portal's March 2024 directive following 22 rabies-related deaths early in the year, calling for immediate vaccination coverage. Supporting this industrial scale, Zoetis reported $8.5 billion in total revenue in their February 2024 financial results, reflecting the massive capital backing animal health product development.

Market Challenge

A major barrier to the global dog vaccines market is the intricate regulatory framework governing veterinary biologics, which demands rigorous safety protocols, efficacy testing, and mandatory clinical trials. This fragmented international landscape compels manufacturers to invest heavily in region-specific compliance, diverting resources from research and development. Consequently, these stringent standards create high entry barriers that discourage smaller biotechnology firms and tend to consolidate market power among a few dominant entities.

Additionally, prolonged approval cycles significantly delay the commercialization of new immunization solutions, hindering the industry's response to emerging infectious diseases. Data from the Animal Health Institute in 2024 indicates that the review and approval process for new veterinary biologics takes between five and seven years. This extended timeline limits the speed at which manufacturers can launch products, while the high financial burden of sustaining such development phases reduces the return on investment and limits the frequency of necessary new vaccine introductions.

Market Trends

The rise of Therapeutic Immunotherapies for Canine Oncology marks a shift from purely prophylactic care to curative biological interventions, utilizing autologous tumor antigens or recombinant proteins to target malignancies like osteosarcoma. This approach offers a precision alternative to traditional chemotherapy with reduced systemic toxicity, aiming to extend the lives of patients with aggressive tumors. As reported by Vet Candy in August 2025, clinical trials for a novel EGFR/HER2-targeting vaccine showed a significant improvement in 12-month survival rates, jumping from approximately 35% to 60%.

Concurrently, the adoption of Recombinant and DNA Vaccine Technologies is reshaping manufacturing by replacing conventional inactivated pathogens with genetically engineered vectors. This technology produces highly pure, non-infectious antigens that improve safety and allow for the differentiation of infected from vaccinated animals (DIVA), which is vital for disease eradication. Major players are scaling these platforms, as evidenced by Merck Animal Health's reported full-year sales of $5.9 billion in February 2025, underscoring the strong commercial demand for advanced animal health innovations.

Key Market Players

• Zoetis Inc.
• Bioveta a.s
• Hester Biosciences Limited
• Boehringer Ingelheim International GmbH
• Brilliant Bio Pharma Private Limited
• Heska Corporation
• Merck & Co., Inc.
• Virbac S.A.
• Zendal Group
• Elanco Animal Health Incorporated

Report Scope

In this report, the Global Dog Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dog Vaccines Market, By Vaccine Type

• Modified/ Attenuated Live
• Inactivated (Killed)
• Others

Dog Vaccines Market, By Disease Type

• Canine Distemper
• Canine Infectious Respiratory Disease Complex (CIRDC)
• Canine Parvovirosis/ Parvovirus Disease
• Canine Leptospirosis
• Canine Lyme Disease
• Infectious Canine Hepatitis
• Canine Rabies
• Others

Dog Vaccines Market, By Duration of Immunity

• 1 Year
• 3 Year
• Others

Dog Vaccines Market, By Route of Administration

• Injectables
• Intranasal
• Oral

Dog Vaccines Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dog Vaccines Market.

Available Customizations:

Global Dog Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dog Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Vaccine Type (Modified/ Attenuated Live, Inactivated (Killed), Others)
  • 5.2.2. By Disease Type (Canine Distemper, Canine Infectious Respiratory Disease Complex (CIRDC), Canine Parvovirosis/ Parvovirus Disease, Canine Leptospirosis, Canine Lyme Disease, Infectious Canine Hepatitis, Canine Rabies, Others)
  • 5.2.3. By Duration of Immunity (1 Year, 3 Year, Others)
  • 5.2.4. By Route of Administration (Injectables, Intranasal, Oral)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Dog Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vaccine Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Duration of Immunity
  • 6.2.4. By Route of Administration
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dog Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Vaccine Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Duration of Immunity
      • 6.3.1.2.4. By Route of Administration
  • 6.3.2. Canada Dog Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Vaccine Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Duration of Immunity
      • 6.3.2.2.4. By Route of Administration
  • 6.3.3. Mexico Dog Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Vaccine Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Duration of Immunity
      • 6.3.3.2.4. By Route of Administration

7. Europe Dog Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vaccine Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Duration of Immunity
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Dog Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vaccine Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Duration of Immunity
      • 7.3.1.2.4. By Route of Administration
  • 7.3.2. France Dog Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vaccine Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Duration of Immunity
      • 7.3.2.2.4. By Route of Administration
  • 7.3.3. United Kingdom Dog Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vaccine Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Duration of Immunity
      • 7.3.3.2.4. By Route of Administration
  • 7.3.4. Italy Dog Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Vaccine Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Duration of Immunity
      • 7.3.4.2.4. By Route of Administration
  • 7.3.5. Spain Dog Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Vaccine Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Duration of Immunity
      • 7.3.5.2.4. By Route of Administration

8. Asia Pacific Dog Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vaccine Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Duration of Immunity
  • 8.2.4. By Route of Administration
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dog Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vaccine Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Duration of Immunity
      • 8.3.1.2.4. By Route of Administration
  • 8.3.2. India Dog Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vaccine Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Duration of Immunity
      • 8.3.2.2.4. By Route of Administration
  • 8.3.3. Japan Dog Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vaccine Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Duration of Immunity
      • 8.3.3.2.4. By Route of Administration
  • 8.3.4. South Korea Dog Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vaccine Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By Duration of Immunity
      • 8.3.4.2.4. By Route of Administration
  • 8.3.5. Australia Dog Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vaccine Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By Duration of Immunity
      • 8.3.5.2.4. By Route of Administration

9. Middle East & Africa Dog Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vaccine Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Duration of Immunity
  • 9.2.4. By Route of Administration
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Dog Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vaccine Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Duration of Immunity
      • 9.3.1.2.4. By Route of Administration
  • 9.3.2. UAE Dog Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vaccine Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Duration of Immunity
      • 9.3.2.2.4. By Route of Administration
  • 9.3.3. South Africa Dog Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vaccine Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Duration of Immunity
      • 9.3.3.2.4. By Route of Administration

10. South America Dog Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vaccine Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Duration of Immunity
  • 10.2.4. By Route of Administration
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dog Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vaccine Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Duration of Immunity
      • 10.3.1.2.4. By Route of Administration
  • 10.3.2. Colombia Dog Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vaccine Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Duration of Immunity
      • 10.3.2.2.4. By Route of Administration
  • 10.3.3. Argentina Dog Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vaccine Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Duration of Immunity
      • 10.3.3.2.4. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Dog Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bioveta a.s
• 15.3. Hester Biosciences Limited
• 15.4. Boehringer Ingelheim International GmbH
• 15.5. Brilliant Bio Pharma Private Limited
• 15.6. Heska Corporation
• 15.7. Merck & Co., Inc.
• 15.8. Virbac S.A.
• 15.9. Zendal Group
• 15.10. Elanco Animal Health Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer